Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-02T20:44:48.747Z Has data issue: false hasContentIssue false
  • English
  • Français

The Transfer of Vaccine Technology to Developing Countries: The Latin American Experience

Published online by Cambridge University Press:  14 October 2009

Akira Homma  and
Robert F. Knouss
Akira Homma
Affiliation:
The Pan American Health Organization
Robert F. Knouss
Affiliation:
The Pan American Health Organization
Get access Rights & Permissions [Opens in a new window]

Abstract

Technological advances by developed countries are producing safer, more potent vaccines. In addition, the transfer of the technology of vaccine production to some developing countries has been taking place during the past five decades, thereby making possible the participation of developing countries in the production and supply of the essential biologicals that are required for immunization programs. Examples of successful transfers of technology, the decisive elements and factors that contribute to the transfers, and the major obstacles to such transfers are presented.

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 1 , Winter 1994 , pp. 47 - 54
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Ada, G. L. Highlights of the conference. In Bankowski, Z., & Ada, G. L. (eds.) Health technology transfer: Whose responsibility?, Geneva, Switzerland: Council for International Organizations of Medical Sciences, 1990, 4–16.Google Scholar
2.Bader, M. B.The international transfer of medical technology-An analysis and a proposal for effective monitoring. International Journal of Health Services, 1977, 7, 443–58.CrossRefGoogle Scholar
3.Bonair, A., Rosenfield, P., & Tengvald, K.Medical technologies in developing countries: Issues of technology development, transfer, diffusion and use. Social Sciences and Medicine, 1989, 28, 769–81.CrossRefGoogle ScholarPubMed
4.Cilingiroglu, A.Transfer of technology for pharmaceutical chemicals. Paris: Organization for Economic Cooperation and Development, 1975.Google Scholar
5.Freeman, P.Vaccines for Latin America: An innovative regional system. Genewatch, 1990, 6, 2–3, 6–9.Google Scholar
6.Fuenzalida, E., & Palacios, R.Un metodo para la preparacion de la vacuna antirabica. Boletin del instituto bacteriologico de Chile, 1955, 8, 3–10.Google Scholar
7.Halstead, S. B. The contribution of the Rockefeller Foundation to the epidemiology and control of yellow fever. In: Homma, A. (ed.), Simposio international sobre febre amarela e dengue: Cinquentendrio da introducao da cepa 17D no Brasil. Rio de Janeiro: FIOCRUZ, 1988, 15–23.Google Scholar
8.Institute of Medicine. New vaccine development, vol. 1: Establishment of priorities: Diseases of importance in the United States. Washington, DC: National Academy Press, 1986.Google Scholar
9.Lages, A. C. A., & Homma, A.Case study on transfer of measles vaccine technology from Japan to Brazil. Paper presented at Latin American Studies Association (National Conference), Miami, FL, 1986.Google Scholar
10.Marshall, E.Malaria vaccine on trial at last? Science, 1992, 255, 1063–64.CrossRefGoogle ScholarPubMed
11.Morgan, P. W.Technology transfer-The role of venture capital. Journal of Medical Engineering and Technology, 1987, 11, 249–54.CrossRefGoogle ScholarPubMed
12.Nicolau, A. R. Producao da vacina anti-amarilica no Brasil. In Homma, A. (ed.), Simposio international sobre febre amarela e dengue. Cinquentendrio da introducao da cepa 17D no Brasil. Rio de Janeiro: FIOCRUZ, 1988, 168–69.Google Scholar
13.Oliva, O. P., Chaves, J. R., Loureiro, M. L., et al. Vacina CAM-70 contra o sarampo produzida no Brasil. A valiacao de campo em criancas com 6–7 meses de idade. Fundacao SESP, Boletin Epidemiologico, 1986, 21/26.Google Scholar
14.Pan American Health Organization. SIREVA: Regional system for vaccines, a feasibility study. Washington, DC, 1991.Google Scholar
15.Perry, S.Diffusion of new technologies: Rational and irrational. Journal of Health Care Technology, 1984, 1, 73–88.Google ScholarPubMed
16.Pinheiro, F. P., Gomes, M. L., & Oliva, O. P. Immune response to yellow fever vaccine. In A symposium on yellow fever-PAHO. Belem, 1980.Google Scholar
17.World Health Organization. Program for vaccine development and transdisease vaccinology: Activities and projects. Geneva, Switzerland, 1989.Google Scholar
18.World Health Organization. Program for vaccine development and transdisease vaccinology. Report of the seventh session of the Scientific Advisory Group of Expert (SAGE). Geneva, Switzerland, June, 1990, 25–27.Google Scholar